The content on this site is intended for healthcare professionals only
ASCO: Bevacizumab and standard adjuvant chemotherapy: no improvement in disease-free survival for early-stage colon cancer
Published: 17 Jun 2009
Views: 13184
Dr Norman Wolmark - Chairman Dept of Human Oncology, Allegheny General Hospital, US
ASCO press conference: Adding bevacizumab (avastin) to standard adjuvant chemotherapy does not improve disease-free survival for early-stage colon cancer
- Categories:
- Colorectal & gastro
Related Videos
Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid ...
Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia
14 Apr 2022
Tumour agnostic treatments in GI cancer
Dr Nicola Normanno and Dr Katja Schmitz
1 Feb 2022
Early treatment discontinuation and early oxaliplatin discontinuation for stage ...
Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France
27 Jan 2022
Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatme...
Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan
25 Jan 2022
Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC
Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
20 Jan 2022
Cancer Health Disparities Special Issue - Editorial
Prof Folakemi Odedina - University of Florida, Tampa, USA
14 Oct 2021
Nivolumab plus chemotherapy or ipilimumab vs chemotherapy as first-line treatmen...
Dr Yelena Janjigian - Memorial Sloan Kettering Center, New York, USA
14 Oct 2021
Pathogenesis of colon adenocarcinoma in Kerala, India
Dr Prasanth Ariyannur - Amrita Institute of Medical Sciences and Research Center...
12 Oct 2021
Radioembolisation with chemotherapy for colorectal liver metastases
Dr Mary Mulcahy - Northwestern Memorial Hospital, Chicago, USA
28 Sep 2021